BOSTON--(BUSINESS WIRE)--Odyssey Therapeutics, Inc., a biotechnology company pioneering next-generation precision immunomodulators for inflammatory diseases, today announced the appointment of two Directors to its Board: Timothy P. Walbert, former Chairman, President and Chief Executive Officer (CEO) of Horizon Therapeutics, and Ian F.

波士顿--（商业新闻短讯）--Odyssey Therapeutics，Inc.，一家开创下一代炎症性疾病精密免疫调节剂的生物技术公司，今天宣布任命两位董事为董事会成员：Horizon Therapeutics前董事长、总裁兼首席执行官（CEO）Timothy P.Walbert和Ian F。

Smith, senior advisor at Bain Capital Life Sciences and former Executive Vice President and Chief Operating Officer (COO) of Vertex Pharmaceuticals. Together, these individuals have decades of senior leadership experience in building global biopharmaceutical companies..

贝恩资本生命科学公司高级顾问、Vertex制药公司前执行副总裁兼首席运营官（COO）。总之，这些人在建立全球生物制药公司方面拥有数十年的高级领导经验。。

“Tim’s legacy in the industry is hallmarked by the acquisition, development and commercialization of numerous life-changing therapies at Horizon that led to one of the largest biopharma acquisitions in recent years. Similarly, Ian was instrumental in evolving Vertex from its early stages into a global market leader – a testament to his financial acumen and ability to drive strategic growth,” said Jeff Leiden, M.D., Ph.D., Chairman of the Odyssey Board..

奥德赛董事会主席杰夫·莱顿（Jeff Leiden）医学博士表示：“蒂姆（Tim）在该行业的遗产是地平线（Horizon）众多改变生命疗法的收购、开发和商业化，这导致了近年来规模最大的生物制药收购之一。同样，伊恩（Ian）在Vertex从早期阶段发展成为全球市场领导者方面发挥了重要作用，证明了他在财务上的敏锐性和推动战略增长的能力。”。。

Timothy P. Walbert has more than 30 years of senior-level leadership and advisory expertise for global biopharmaceutical companies. For 15 years, he served as Chairman, President and CEO of Horizon Therapeutics, where he oversaw the acquisition, development and commercial launch of a dozen products for autoimmune and inflammatory diseases, leading to approximately $4 billion in net sales in 2023, and ultimately, Horizon’s $28.3 billion acquisition by Amgen the same year.

蒂莫西·沃尔伯特（Timothy P.Walbert）在全球生物制药公司拥有30多年的高级领导和咨询专业知识。15年来，他担任Horizon Therapeutics的董事长、总裁兼首席执行官，监督了十几种针对自身免疫性疾病和炎症性疾病的产品的收购、开发和商业推出，导致2023年净销售额约为40亿美元，最终导致Horizon于同年被安进283亿美元收购。

He serves as a senior advisor to Amgen’s executive leadership and is a member of the Board of Directors for several companies, including COUR Pharmaceuticals, Sagimet Biosciences, Mirum Pharmaceuticals and Century Therapeutics..

他是安进高管层的高级顾问，也是多家公司的董事会成员，包括COUR Pharmaceuticals、Sagimet Biosciences、Mirum Pharmaceuticals和Century Therapeutics。。

Previously, Mr. Walbert was President, CEO and Director of IDM Pharma and Executive Vice President of Commercial Operations at NeoPharm. Before that, as the Divisional Vice President and General Manager of Immunology at Abbott (AbbVie), Mr. Walbert led the development and launch of HUMIRA®, a blockbuster product, and was also the Divisional Vice President of Global Cardiovascular Strategy.

此前，沃尔伯特先生曾任IDM Pharma总裁、首席执行官兼董事，以及NeoPharm商业运营执行副总裁。在此之前，作为雅培（AbbVie）免疫学部门副总裁兼总经理，Walbert先生领导了HUMIRA®的开发和推出，HUMIRA®是一款畅销产品，也是全球心血管战略部门副总裁。

Earlier in his career, Mr. Walbert held roles of increasing responsibility at G.D. Searle & Company, where he led the CELEBREX® North America marketing team, as well as at Merck, Wyeth and H.J. Heinz. He received a Bachelor of Arts degree in business and marketing from Muhlenberg College in Pennsylvania..

。他在宾夕法尼亚州的穆伦伯格学院获得了商业和市场营销文学学士学位。。

Ian F. Smith is a 30-year industry veteran with deep expertise in corporate strategy, finance and business development for biotech companies. Between 2001 and 2019, he served in various roles at Vertex, including as Executive Vice President and COO, and Chief Financial Officer, where during his tenure, he was responsible for the financial strategy and operations of Vertex and played a core role in the company’s transition from a research-focused biotech to a multi-billion-dollar, global organization with market-leading products approved for chronic, life-shortening genetic diseases, including cystic fibrosis..

伊恩·史密斯（IanF.Smith）拥有30年的行业经验，在生物技术公司的企业战略、财务和业务发展方面拥有丰富的专业知识。2001年至2019年间，他在Vertex担任过多个职位，包括执行副总裁兼首席运营官和首席财务官。在任职期间，他负责Vertex的财务战略和运营，并在该公司从专注于研究的生物技术转变为数十亿美元的全球组织的过程中发挥了核心作用，该组织的市场领先产品被批准用于慢性，缩短寿命的遗传疾病，包括囊性纤维化。。

Mr. Smith serves as Chairman of the Board of Directors of Rivus Pharmaceuticals and iVexSol, Executive Chairman of the Board of Solid Biosciences and a member of the Board of Alkeus Pharmaceuticals, Foghorn Therapeutics and Stoke Therapeutics. He received a Bachelor of Arts with honors in accounting and finance from Manchester Metropolitan University in England..

史密斯先生担任Rivus Pharmaceuticals和iVexSol董事会主席，Solid Biosciences董事会执行主席，以及Alkeus Pharmaceuticals、Foghorn Therapeutics和Stoke Therapeutics董事会成员。他获得了英国曼彻斯特大都会大学（Manchester Metropolitance University）的会计和金融荣誉文学士学位。。

“Tim and Ian have each played pivotal roles in creating companies that deliver novel medicines that have profoundly impacted the lives of patients worldwide. As we advance our lead programs into and through the clinic and grow into a multi-product, development-stage company, we look forward to leveraging the insights of Ian, Tim and the rest of our accomplished Board,” said Gary D.

Gary D说：“Tim和Ian在创建公司方面都发挥了关键作用，这些公司提供的新药对全世界患者的生活产生了深远的影响。随着我们将领先项目推进到诊所，并通过诊所成长为一家多产品、发展阶段的公司，我们期待着利用Ian、Tim和我们其他成功董事会的见解。”。

Glick, Ph.D., founder and CEO of Odyssey Therapeutics..

Glick博士，Odyssey Therapeutics创始人兼首席执行官。。

About Odyssey Therapeutics

关于Odyssey Therapeutics

Odyssey Therapeutics is a clinical-stage biotechnology company focused on discovering, developing and commercializing the next generation of inflammatory precision medicines. Since its founding in 2021, Odyssey has rapidly advanced a pipeline of clinical- and research-stage programs, leveraging the scientific expertise of its team of drug hunters and a comprehensive suite of tools to tackle drug targets with the greatest potential to benefit patients.

Odyssey Therapeutics是一家临床阶段的生物技术公司，专注于发现，开发和商业化下一代炎症精确药物。自2021年成立以来，奥德赛（Odyssey）迅速推进了一系列临床和研究阶段的项目，利用其药物猎手团队的科学专业知识和一整套工具来应对最有可能使患者受益的药物目标。

Odyssey’s mission is to create extraordinary leaps in patient outcomes and change the standard of care for those living with serious inflammatory diseases. For more information, please visit odysseytx.com and follow Odyssey Therapeutics on X (formerly Twitter) and LinkedIn..

奥德赛的使命是在患者预后方面取得非凡的飞跃，并改变那些患有严重炎症性疾病的患者的护理标准。有关更多信息，请访问odysseytx.com，并在X（以前的Twitter）和LinkedIn上关注Odyssey Therapeutics。。